Interleukin-6 Cytokine: A Multifunctional Glycoprotein for Cancer
- Corresponding Author:
- Paul Zarogoulidis, M.D, Ph.D
Pulmonary Department-Oncology Unit
“G. Papanikolaou” General Hospital
Aristotle University of Thessaloniki
E-mail: [email protected]
Received date: July 17, 2013; Accepted date: August 07, 2013; Published date: August 12, 2013
Citation: Zarogoulidis P, Yarmus L, Darwiche K, Walter R, Huang H, et al. (2013) Interleukin-6 Cytokine: A Multifunctional Glycoprotein for Cancer. Immunome Res 9:062. doi: 10.4172/2090-5009.1000062
Copyright: © 2013 Zarogoulidis P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Interleukin 6 is a multifunctional cytokine. Its increased levels have been associated with elevated cancer risk, and also these levels have been found to be a prognostic factor for several cancer types. In addition, increased levels have been found in coronary heart disease, insulin resistant patients, advance stage cancer patients, atopy/asthma and in patients with blood circulating micrometastasis. Additionally several studies with different types of cancers have been performed to identify the correlation between interleukin-6 levels, stage, treatment response and severity of symptoms. The influence of interleukin-6 is performed mainly through the janus kinase-signal transducer and activator of transcription-zinc finger protein 1-2 signaling pathway. As a result, the increased levels of interleukin-6 are responsible for enhanced neo-angiogenesis, inhibition of cancer cell apoptosis and deregulation of the control mechanisms in the microenvironment. In addition, increased levels of inteleukin-6 have been found to increase the production of collagen and a-actin which induce interstitial lung disease. In the current mini review we will present information regarding the interleukin-6 and published results in several cancer studies and finally we will comment in future treatment approaches blocking this cytokine in cancer patients.